Skip to main content
Premium Trial:

Request an Annual Quote

GeneData Licenses Expressionist Software to DiaDexus

NEW YORK, Sept. 4 – Swiss bioinformatics company GeneData said Tuesday it has licensed its Expressionist microarray data analysis system to DiaDexus of Santa Clara, Calif.

"We chose GeneData Expressionist because of its superior ability to support various technologies and GeneData's willingness to further customize its system," Ron Lindsay, chief scientific officer for DiaDexus, said in a statement.

"GeneData will be instrumental in supporting our in-house system for rapidly screening thousands of human genes for their potential involvement in diseases," Lindsay added. 

DiaDexus aims to turn genomic sequence information into therapeutics and diagnostics.

Financial terms of the deal were not disclosed.

GeneData said that its system is capable of handling data from various technologies, including those belonging to Affymetrix and Agilent.

GeneData of Basel, Switzerland, has recently opened offices in San Francisco and Boston. 

The Swiss company’s customers include Aventis, Bayer, MediGene, MWG-Biotech, Philip Morris, Schering, and Syngenta. 

In April, Affymetrix agreed to a non-exclusive deal to market the Expressionist software for analysis of microarray gene expression data.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.